Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mecamylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 1.00 |
| ▸ | CHRNB4 known ✓ | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA3 known ✓ | P32297 | 4/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 3/20 | 1.00 |
| ▸ | CHRNG | P07510 | 3/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 3/20 | 1.00 |
| ▸ | CHRND | Q07001 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | CHRNE | Q04844 | 1/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2(R)-Mecamylamine SCHEMBL308575 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL11028235 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL3008785 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Dexmecamylamine SCHEMBL29376444 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL3007951 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL34252 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL4416036 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL7208020 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL592362 | 0.97 | CHRNB2 (0.95) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL7440931 | 0.97 | CHRNB2 (0.95) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320618-A | Epoxy adhesive for semiconductor cutting and splicing rod and preparation method thereof | 杭州得力科技股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| CN-111732704-B | Polyurethane adhesive for 121 ℃ high-temperature-cooking-resistant water-based gravure printing ink and preparation method thereof | 旭川化学（苏州）有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-111732704-A | Polyurethane adhesive for 121 ℃ high-temperature-cooking-resistant water-based gravure printing ink and preparation method thereof | 旭川化学（苏州）有限公司 | 2020-10-02 | — | — | CN | claimed |
| EP-2237799-B1 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2019-04-10 | — | — | EP | claimed |
| EP-2338360-B1 | ALEXIPHARMIC CIGARETTE FILTER MATERIAL AND ITS PREPARATION | LIANG YONGLIN (CN) | 2018-04-18 | — | — | EP | claimed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | claimed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | claimed |
| CN-102441496-B | Method for selecting potassium feldspars in potassium-bearing tailings | ZHONGKEXIANG TIANJIN TECHNOLOGY CO LTD | 2013-07-10 | — | — | CN | claimed |
| US-20110162664-A1 | ALEXIPHARMIC CIGARETTE FILTER MATERIAL AND THEIR PRAPARATION | LIANG YONGLIN | 2011-07-07 | — | — | US | claimed |
| EP-2338360-A1 | ALEXIPHARMIC CIGARETTE FILTER MATERIAL AND THEIR PRAPARATION | Liang, Yonglin (CN) | 2011-06-29 | — | — | EP | claimed |
| JP-2011510954-A | — | — | 2011-04-07 | — | — | JP | claimed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | claimed |
| EP-2237799-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | Ascendis Pharma AS (DK) | 2010-10-13 | — | — | EP | claimed |
| WO-2009095479-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2009-08-06 | — | — | WO | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| CN-122029489-A | Photosensitive resin composition, cured product, display device, and electronic component | 东丽株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-4167611-A | Method of production of compositions which exhibit no shrinkage or which increase in volume during setting | POLITECHNIKA WARSZAWASKA (PL) | 1979-09-11 | — | — | US | disclosed |
| US-3957832-A | EPOXY RESINS PREPARED FROM POLYHYDROXY-CONTAINING COMPOUNDS | THE DOW CHEMICAL COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRNB2 3361/4885CHRNB4 3426/4885CHRNA3 1885/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | CHRNB2 2627/4885CHRNB4 2922/4885CHRNA3 3474/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | CHRNB2 3364/4885CHRNB4 3425/4885CHRNA3 1890/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | CHRNB2 376/4885CHRNB4 682/4885CHRNA3 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.